New biotech company Civetta Therapeutics has closed a $53 million Series A financing round to develop drugs that target “propeller proteins” as a way of treating cancers and other diseases. Propeller proteins are found throughout nature, and the circularly arranged “blades” of these proteins commonly serve as active sites to which molecules can bind. Bruce … Continue reading “Civetta Therapeutics Unveils a Propeller Protein Plan, $53M in Funding”
FDA Green Lights Sight Diagnostics’ Finger-Prick Blood Test
Sight Diagnostics today announced it has received US FDA 510(k) clearance to use its patented OLO analyzer, which performs a complete blood count using two drops of blood. The FDA clearance gives hospital-run laboratories, diagnostic providers, and outpatient clinics the go-ahead to use the device, which captures around 1,000 images that are then interpreted by … Continue reading “FDA Green Lights Sight Diagnostics’ Finger-Prick Blood Test”
Digital Health Survivors & Innovative Incumbents Must Team Up for True Disruption
Editor’s note: This is Part 2 of a two-part post about innovation in digital health, co-authored by Rob Coppedge, CEO of Echo Health Ventures. Read Part 1 here. The Path Forward Between Echo Health Ventures and Blue Cross and Blue Shield of North Carolina, we work deeply on both sides of these partnerships and have perspective … Continue reading “Digital Health Survivors & Innovative Incumbents Must Team Up for True Disruption”
Roche Notches FDA Nod in Lung Cancer, Amps Up Competition With Merck
A Roche immunotherapy has won an additional FDA approval as a first-line treatment for non-small lung cancer, bolstering the product’s competitive stance versus one from Merck. The FDA approved atezolizumab (Tecentriq) for adults whose non-squamous non-small cell lung cancer (NSCLC) is metastatic, meaning it has spread, and does not have the EGFR or ALK genetic … Continue reading “Roche Notches FDA Nod in Lung Cancer, Amps Up Competition With Merck”
GHO Capital Raises Over $1bn, Eyes Biotech Outsourcing Services
GHO Capital will use the money raised to invest in healthcare, including outsourced service providers, which are seeing demand from smaller biotechs, according to a Jefferies analyst. GHO Capital raised €975 million ($1.1 billion), which exceeded its €800 million target, and is 50% larger than its 2015 maiden fund. Fund II LP is the largest … Continue reading “GHO Capital Raises Over $1bn, Eyes Biotech Outsourcing Services”
Stemonix, Atomwise Team Up on Drug Discovery With MicroOrgans and AI
Two venture-backed startups that have developed technologies intended to speed up the drug discovery and development process are combining those tools in a bid to achieve their goals together. San Francisco-based Atomwise has developed deep learning techniques for use in structure-based small molecule drug discovery. Since 2012 it has raised more than $50 million to … Continue reading “Stemonix, Atomwise Team Up on Drug Discovery With MicroOrgans and AI”
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
[Updated 12/4/19, 4:01 p.m. ET. See below.] Veracyte, a company whose tests help physicians make treatment decisions, is adding technology from NanoString to the fold to expand its diagnostic capabilities. South San Francisco-based Veracyte (NASDAQ: [[ticker:VCYT]]) announced Tuesday that it has reached a deal for global rights to develop and commercialize diagnostics based on the … Continue reading “Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal”
Repare Therapeutics Taps Clementia Pharma’s Steve Forte As Its New CFO
Repare Therapeutics said Tuesday it has appointed Steve Forte as executive vice president and chief financial officer. The company, which has offices in Cambridge, MA and Montreal is developing immune-oncology drugs by leveraging a concept known as synthetic lethality. In 2017 it emerged from stealth with $68 million in outside financing to advance its efforts; in September it … Continue reading “Repare Therapeutics Taps Clementia Pharma’s Steve Forte As Its New CFO”
Partner or Die: How to Succeed Even After the Digital Health Hype Quiets Down
Editor’s note: This is Part 1 of a two-part piece on innovation in digital health, co-authored by Bryony Winn, chief strategy and innovation officer at Blue Cross and Blue Shield of North Carolina. Read Part 2 here. More than 6,500 people descended on HLTH in Las Vegas in late October to “solve the most pressing … Continue reading “Partner or Die: How to Succeed Even After the Digital Health Hype Quiets Down”
Caraway Therapeutics Names Martin Williams as CEO
Cambridge, MA-based Caraway Therapeutics has named Martin Williams as its CEO. Williams joins the company, which is looking to treat neurodegenerative diseases by preserving neurons, from Yuma Therapeutics where he was the executive chairman. He will remain on Yuma’s board of directors. With more than 30 years of industry experience, Williams has held several leadership … Continue reading “Caraway Therapeutics Names Martin Williams as CEO”
A Safer CRISPR? Cyrus, Broad Institute Look to Quell Concerns
Cyrus Biotechnology and the Broad Institute of MIT and Harvard have teamed up to make gene editing with the CRISPR-Cas9 technology safer. The multi-target collaboration, specific details of which are not being disclosed, aims to address longstanding concerns surrounding gene editing: some patients might be predisposed to an immune reaction to the DNA-cutting enzyme Cas9. … Continue reading “A Safer CRISPR? Cyrus, Broad Institute Look to Quell Concerns”
Astellas Bets On Gene Therapy With $3B Audentes Acquisition Offer
Japanese drug giant Astellas Pharma announced late Monday it has agreed to buy Audentes Therapeutics, which is developing gene therapies for rare neuromuscular diseases. It’s an all-cash deal worth $3 billion, with the Astellas offer of $60 per share representing a 110 percent premium to Audentes’ (NASDAQ: [[ticker:BOLD]]) share price of $28.61 apiece at market close … Continue reading “Astellas Bets On Gene Therapy With $3B Audentes Acquisition Offer”
Neurocrine Inks $50M Xenon Pharma Deal to Expand Into Epilepsy
Neurocrine Biosciences is paying $30 million cash and taking a $20 million equity stake in Xenon Pharmaceuticals to license a clinical-stage epilepsy drug and collaborate on other potential treatments for the seizure-causing brain disorder. The Xenon (NASDAQ: [[ticker:XENE]]) deal is the second one San Diego-based Neurocrine (NASDAQ: [[ticker:NBIX]]) has struck this year in a bid … Continue reading “Neurocrine Inks $50M Xenon Pharma Deal to Expand Into Epilepsy”
Curtis Ruegg to Succeed Amphivena Founder As New CEO, President
Curtis Ruegg will join Amphivena Therapeutics as president and CEO as the company’s founder Jeanmarie Guenot transitions to an advisory role. The San Francisco company, which has raised $88.5 million from outside investors, is is developing a type of immunotherapy called T cell engagers. Ruegg joins Amphivena from Parvus Therapeutics, where he held the same … Continue reading “Curtis Ruegg to Succeed Amphivena Founder As New CEO, President”
IFM’s Glick Becomes Executive Chairman, Seidel Promoted to CEO
Gary Glick, co-founder and CEO of IFM Therapeutics, is moving on from his executive role to become executive chairman of the company’s board of directors. To take his place, Boston-based IFM promoted Martin Seidel, the company’s vice president of research and development, to CEO. He is also joining the company’s board. The personnel changes came … Continue reading “IFM’s Glick Becomes Executive Chairman, Seidel Promoted to CEO”
Agenus Chief Technology Officer Alex Duncan to Depart in January
Alex Duncan, chief technology officer of Agenus (NASDAQ: [[ticker:AGEN]]) for nearly four years, is leaving on Jan. 2, the company disclosed in a securities filing Friday. No reason was given for Duncan’s departure. Lexington, MA-based Agenus develops cancer drugs. Last year, Agenus struck a $150 million deal with Gilead Sciences (NASDAQ: [[ticker:GILD]]), which acquired global rights … Continue reading “Agenus Chief Technology Officer Alex Duncan to Depart in January”
IFM Lands $55.5M to Launch NewCo Quattro and Discovery Incubator
IFM Therapeutics has raised $55.5 million to launch its third drug subsidiary as well as an incubator, both of which are focused on developing new therapies for inflammatory diseases and cancers. Those endeavors will be led by a familiar face. Boston-based IFM has promoted its vice president of research and development, Martin Seidel, to become … Continue reading “IFM Lands $55.5M to Launch NewCo Quattro and Discovery Incubator”
Deep 6 AI Adds $17M To Advance Clinical Trial Recruitment Software
Software startup Deep 6 AI has developed a system that analyzes a range of patient health records to accelerate the process of identifying candidates for clinical trial recruitment—a longstanding bottleneck in the drug development process. The Pasadena, CA-based company, founded in 2015, recently raised $17M in Series A funding to advance its software system, which … Continue reading “Deep 6 AI Adds $17M To Advance Clinical Trial Recruitment Software”
Biotech VC Down 20% in US as Policies Drive Away Foreign Investors, BIO Says
Reforms to a US national security regulation are putting off foreign investors and driving down VC investment in the biotech space by as much as 20 percent, says BIO’s David Thomas. In August 2018, Congress passed the Foreign Investment Risk Review Modernization Act (FIRRMA) as part of the Fiscal 2019 National Defense Authorization Act. The … Continue reading “Biotech VC Down 20% in US as Policies Drive Away Foreign Investors, BIO Says”
AstraZeneca, Novoheart to Co-Develop New Heart Model
AstraZeneca has turned to Novoheart’s “human heart-in-a-jar” technology to create a preclinical model that mimics a form of heart failure for which there is no effective therapy available. Based on Novoheart’s human ventricular cardiac organoid chamber (hvCOC) technology, the companies are aiming to develop a new in vitro model that can reproduce the characteristics of … Continue reading “AstraZeneca, Novoheart to Co-Develop New Heart Model”
La Jolla Pharma’s Share Price Halves On Trial End, CEO Departure
La Jolla Pharmaceutical is turning its focus to its lone FDA-approved product and another one in the pipeline after an experimental drug for a rare blood disease failed a late-stage study. On Monday, La Jolla Pharma (NASDAQ: [[ticker:LJPC]]) said it was halting a clinical trial testing LJPC-401, its drug candidate for iron overload in patients … Continue reading “La Jolla Pharma’s Share Price Halves On Trial End, CEO Departure”
AI Startup Healx Looks to Find Repurposable Drugs for Rare Diseases
Off the heels of a $56 million Series B funding round, Cambridge, UK-headquartered Healx is looking to partner with rare disease patient groups to advance treatments toward the clinic. The company’s artificial intelligence-powered drug discovery platform, Healnet, uses both public and proprietary biomedical data to identify and develop repurposed treatments, which are existing drugs that … Continue reading “AI Startup Healx Looks to Find Repurposable Drugs for Rare Diseases”
PhoenixMD Adds Seed Funding to Test Experimental Breast Cancer Drug
Phoenix Molecular Designs, a biotech developing kinase inhibitors to treat cancer, has brought in an undisclosed amount of financing—boosting its total seed funding raised to $12 million. The San Diego-based biotech says the proceeds will help fund the Phase 1/1b clinical trial of its lead candidate, PMD-026, an investigational cancer drug being developed to treat … Continue reading “PhoenixMD Adds Seed Funding to Test Experimental Breast Cancer Drug”
Global Blood’s Sickle Cell Drug Wins FDA Approval Ahead of Schedule
The FDA on Monday approved a Global Blood Therapeutics treatment for sickle cell disease, three months before the agency’s decision was expected. Regulators evaluated the drug, voxelotor (Oxbryta), under a pathway that allows for a speedier review using less evidence than is typically required. This pathway is reserved for drugs that address an unmet medical … Continue reading “Global Blood’s Sickle Cell Drug Wins FDA Approval Ahead of Schedule”
Ferring and Blackstone Team Up to Fund Gene Therapy Firm With $570M
Ferring Pharmaceuticals and Blackstone Life Sciences have formed a new company to commercialize a bladder cancer gene therapy that is currently in late-stage clinical testing. The new company, FerGene, is a subsidiary of Swiss pharmaceutical company Ferring, which is investing $170 million in the new unit. Blackstone has committed $400 million. In addition to US … Continue reading “Ferring and Blackstone Team Up to Fund Gene Therapy Firm With $570M”
Five Questions With a16z’s Vijay Pande on AI and Making New Drugs
In startup world these days, the word “biotech” is increasingly accompanied by “computational” and two, two-letter initialisms: AI and ML. Those tools—artificial intelligence and machine learning, respectively—have been around for decades, but in recent years have become faster and cheaper, accelerating their use by those in the business of discovering and developing new drugs. Another … Continue reading “Five Questions With a16z’s Vijay Pande on AI and Making New Drugs”
Axcella Taps Incyte’s Laurent Chardonnet as Chief Financial Officer
Axcella Health (NASDAQ: [[ticker:AXLA]]) announced it has hired Laurent Chardonnet as its chief financial officer. Chardonnet previously spent 15 years in a variety of finance-related roles at Incyte (NASDAQ: [[ticker:INCY]]), during which time it grew from a clinical-stage outfit to a $20 billion commercial-stage biopharma. Cambridge, MA-based Axcella, which was founded by Flagship Pioneering under … Continue reading “Axcella Taps Incyte’s Laurent Chardonnet as Chief Financial Officer”
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
Novartis has agreed to acquire The Medicines Company for $9.7 billion, a cash deal that brings it a compound that is poised to become part of a new wave of cholesterol-lowering drugs. With the acquisition, Swiss pharma giant Novartis (NYSE: [[ticker:NVS]]) aims to compete with two other next-generation cholesterol drugs now being marketed by Amgen … Continue reading “Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B”
Kymera Promotes Nello Mainolfi to President & CEO
Kymera Therapeutics’ new leader comes from within. Nello Mainolfi, the company’s co-founder, president, and chief scientific officer, has been promoted to president and CEO. Mainolfi’s experience includes positions at the Novartis Institutes for Biomedical Research, Atlas Venture, and Raze Therapeutics. He is succeeding former Kymera CEO Laurent Audoly, who announced in July that he would … Continue reading “Kymera Promotes Nello Mainolfi to President & CEO”
Immune-Onc Therapeutics Adds Paul Woodard and An Song to C-Suite
Paul Woodard has joined Immune-Onc Therapeutics as its chief medical officer. He comes to the Palo Alto, CA-based cancer immunotherapy developer from Bellicum Pharmaceuticals (NASDAQ: [[ticker:BLCM]]), where he was senior vice president of clinical and medical affairs. In other moves, Immune-Onc promoted An Song to chief scientific officer. Song was the company’s senior vice president … Continue reading “Immune-Onc Therapeutics Adds Paul Woodard and An Song to C-Suite”
Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More
Bristol-Myers Squibb this week completed its acquisition of Celgene, a $74 billion deal that creates a pharmaceutical juggernaut. And all it took was the largest asset sale ever required by federal antitrust regulators. As the Federal Trade Commission reviewed Bristol’s (NYSE: [[ticker:BMS]]) deal to acquire Celgene, anti-inflammatory drug apremilast (Otezla) emerged as a sticking point. … Continue reading “Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More”
With Cell-By-Cell Take on Drug Discovery, Immunitas Debuts With $39M
A cancer tumor is a veritable patchwork of cells with a variety of genetic fingerprints. Immunitas Therapeutics is using single-cell genomics—an approach that studies the genetic activity of individual cells—to peer deeply into patient tumors and more precisely determine what is fueling the growth. With that knowledge, the company plans to develop new targets for … Continue reading “With Cell-By-Cell Take on Drug Discovery, Immunitas Debuts With $39M”
Azitra Names Jeanne Bertonis as Chief Operating Officer
Jeanne Bertonis has joined Azitra as chief operating officer. In this role, she will be responsible for building the clinical operations team as the company preps for multiple clinical trials in 2020, according to a statement from Azitra CEO Richard Andrews. Bertonis was previously CEO of Visgo Therapeutics – which she co-founded – and has … Continue reading “Azitra Names Jeanne Bertonis as Chief Operating Officer”
Former Shire Exec Robertson Joins Yumanity as Chief Medical Officer
Cambridge, MA-based Yumanity Therapeutics has named Brigitte Robertson to the role of chief medical officer. Most recently, she was the therapeutic area head of neuroscience global clinical development at Shire, which was then acquired by Takeda (NYSE: [[ticker:TAK]]). Robertson also held roles at Sunovion Pharmaceuticals in clinical development and experimental medicine, and GlaxoSmithKline (NYSE: [[ticker:GSK]]) … Continue reading “Former Shire Exec Robertson Joins Yumanity as Chief Medical Officer”
Ex-Novartis Cell & Gene Therapy Exec Chou Joins Aruvant as CEO
William Chou has been appointed CEO of Aruvant Sciences. Chou was most recently a vice president and global disease lead for the Novartis (NYSE: [[ticker:NVS]]) cell and gene therapy unit. Before Novartis, he worked at Boston Consulting Group. Aruvant, which splits its operations between New York and Basel, Switzerland, is developing therapies for severe blood … Continue reading “Ex-Novartis Cell & Gene Therapy Exec Chou Joins Aruvant as CEO”
Relay Therapeutics Names Ben Wolf Chief Medical Officer
Relay Therapeutics has appointed Ben Wolf to serve as chief medical officer, the same position he held most recently at KSQ Therapeutics. His experience also includes positions at Blueprint Medicines (NASDAQ: [[ticker:BPMC]]), Merrimack Pharmaceuticals (NASDAQ: [[ticker:MACK]]), ImmunoGen, Amgen (NASDAQ: [[ticker:AMGN]]), and Genentech. Last year, Cambridge, MA-based Relay raised $400 million for its work developing cancer … Continue reading “Relay Therapeutics Names Ben Wolf Chief Medical Officer”
Alnylam Gets Quick FDA OK for Second RNAi Rare Disease Drug
[Updated 11/21/19, 10:05 a.m. See below.] An Alnylam Pharmaceuticals drug developed to treat a rare, inherited metabolic disorder won FDA approval on Wednesday, the second regulatory nod the company has received for a drug that turns off a gene to prevent it from causing disease. The FDA approved the Alynlam (NASDAQ: [[ticker:ALNY]]) drug givosiran (Givlaari) … Continue reading “Alnylam Gets Quick FDA OK for Second RNAi Rare Disease Drug”
Twist Bioscience Promotes Patrick Finn to Chief Commercial Officer
Twist Bioscience (NASDAQ: [[ticker:TWST]]), a synthetic biology company that has developed a proprietary way of manufacturing DNA by “writing” it on a silicon chip, has promoted Patrick “Paddy” Finn to chief commercial officer, a newly created position. Previously Finn, who joined Twist in 2015, was senior vice president of commercial operations. Prior to Twist he … Continue reading “Twist Bioscience Promotes Patrick Finn to Chief Commercial Officer”
Kronos Bio Appoints Jorge DiMartino as Its Chief Medical Officer
Kronos Bio has named Jorge DiMartino as its chief medical officer and executive vice president, clinical development, a newly created position. DiMartino, who was most recently at Celgene as vice president, translational development, will be based at Kronos headquarters in San Mateo, CA. Kronos, which aims to use its Small Molecule Microarray technology to develop … Continue reading “Kronos Bio Appoints Jorge DiMartino as Its Chief Medical Officer”
Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow
Lucence, a genomic medicine company developing blood-based tests for cancer screening and treatment selection, announced this week the close of a $20 million Series A funding round led by IHH Healthcare. CEO and founder Min-Han Tan (pictured) says the investment will be used to scale the Singapore-based company’s clinical lab operations—notably in the US, with … Continue reading “Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow”
Biopharma Execs Remain Optimistic Despite Political Headwinds
Drug pricing debates and uncertainty associated with Brexit are the issues most likely to keep biopharmaceutical executives awake at night. Nevertheless, senior figures remain optimistic about the industry’s prospects in 2020. These are among the major findings of a survey of 500 industry leaders and investors conducted by investment bank Jefferies. “Nearly half of respondents … Continue reading “Biopharma Execs Remain Optimistic Despite Political Headwinds”
France-Based Tissium Boosts US Work After Closing €38.75M Series B
Tissium is targeting Boston’s biotech scene to advance its platform of proprietary biopolymers after building out its manufacturing capabilities in France. Backed by a €38.75 million ($42.78 million) Series B funding round, the company is moving forward with several development programs examining the polymer’s use in various applications. “Since the inception of the company Boston … Continue reading “France-Based Tissium Boosts US Work After Closing €38.75M Series B”
Myovant to Seek FDA OK on Pill to Treat Advanced Prostate Cancer
A drug candidate once shelved by Takeda Pharmaceutical (NYSE: [[ticker:TAK]]) has found new life within Roivant Sciences spinout Myovant as a potential once-daily oral hormone therapy for patients with advanced prostate cancer. The Brisbane, CA-based biotech company (MYSE: [[ticker:MYOV]]) reported Tuesday that the drug, relugolix, met the primary goal of a Phase 3 trial, lowering … Continue reading “Myovant to Seek FDA OK on Pill to Treat Advanced Prostate Cancer”
Reata Rakes In $505M to Advance Development of Two Rare Disease Drugs
Reata Pharmaceuticals on Tuesday closed a stock sale, raising $505.1 million to advance the company’s two lead drug candidates to regulatory review. Reata’s stock price jumped last week after the company announced its investigational drug, bardoxolone methyl (bard), met the main goal of a Phase 3 clinical trial testing it as a treatment for Alport … Continue reading “Reata Rakes In $505M to Advance Development of Two Rare Disease Drugs”
Novo Ventures Commits $25M to Grow Discovery “Greenhouse” in Boston
Novo Ventures has committed up to $25 million (€23 million) over a five-year period to fund seed-stage drug discovery projects at the Broad Institute of MIT and Harvard in a deal which it says will propel it into the Massachusetts biotech community. The new biotech accelerator, dubbed the Novo Broad Greenhouse, will support between five … Continue reading “Novo Ventures Commits $25M to Grow Discovery “Greenhouse” in Boston”
Inozyme Pharma Names Pedro Huertas Chief Medical Officer
Pedro Heurtas has joined Inozyme Pharma as chief medical officer, the same position he held most recently at Sentien Pharmaceuticals. His experience also includes positions at Eloxx Pharmaceuticals, Genzyme, Shire, and Amicus Therapeutics (NASDAQ: [[ticker:FOLD]]). In other moves, Boston-based Inozyme appointed Gus Khursigara its vice president of medical affairs and clinical operations, and Catherine Nestor … Continue reading “Inozyme Pharma Names Pedro Huertas Chief Medical Officer”
Verseau Therapeutics Names Tim Smith Chief Business Officer
Tim Smith has joined Verseau Therapeutics as its chief business officer. Smith’s experience includes business development roles at Dova Pharmaceuticals, IDEAYA Biosciences (NASDAQ: [[ticker:IDYA]]), Cleave Biosciences, and Celgene (NASDAQ: [[ticker:CELG]]). Bedford, MA-based Verseau is developing a type of cancer immunotherapy called macrophage checkpoint modulators. Last month, the company closed $50 million in Series A financing.
With “Inflection Year” Ahead, Ovid Adds Novartis’s Tardio to C-Suite
About five years ago, former Teva Pharmaceutical CEO Jeremy Levin launched Ovid Therapeutics with a plan to develop treatments for rare brain diseases. Now, with the completion of a clinical trial on the horizon anticipated to provide enough data to file for FDA approval, the 55-person biotech has recruited a Novartis (NYSE: [[ticker:NVS]]) executive to … Continue reading “With “Inflection Year” Ahead, Ovid Adds Novartis’s Tardio to C-Suite”
Underdog Launches With $4M to Target “Toxic” Form of Cholesterol
Underdog Pharmaceuticals has launched with nearly $4 million in seed funding to develop treatments for atherosclerosis, a progressive condition in which arteries become clogged with substances such as fats and cholesterol, which restricts blood flow. Based in Mountain View, CA, Underdog is a spinout of the nonprofit SENS Research Foundation (SRF). Matthew O’Connor and Michael … Continue reading “Underdog Launches With $4M to Target “Toxic” Form of Cholesterol”
Alkermes Eyes Brain Disorders and Beyond With $100M Deal for Rodin
[Updated 5:55 p.m. See below.] Rodin Therapeutics has limited data from human studies about its neurodegeneration drug, but the company’s new approach to treating brain disorders has proven attractive enough for Alkermes to plunk down $100 million to buy the startup. According to financial terms announced Monday, the cash sum is an upfront payment. Depending … Continue reading “Alkermes Eyes Brain Disorders and Beyond With $100M Deal for Rodin”